See the DrugPatentWatch profile for miebo
What Is Miebo and What Does It Treat?
Miebo (perfluorohexyloctane ophthalmic solution) is an FDA-approved eye drop for treating dry eye disease in adults. It targets the signs and symptoms of dry eye by reducing tear evaporation.[1]
How Does Miebo Work in the Eyes?
Miebo forms a protective layer on the eye's surface to prevent tear evaporation, addressing meibomian gland dysfunction—a common cause of dry eye. Apply one drop in each eye twice daily.[1]
Who Makes Miebo and When Was It Approved?
Novartis (through its acquisition of Bausch + Lomb) markets Miebo. The FDA approved it in May 2023, based on two phase 3 trials showing significant improvement in tear break-up time.[1]
Common Side Effects Patients Report
Most users experience no issues, but some report blurred vision (lasting seconds to minutes after dosing), eye redness, or pain. It's preservative-free and pregnancy category unknown—consult a doctor if pregnant.[1]
How Does Miebo Compare to Other Dry Eye Drops?
Unlike Restasis or Xiidra (which suppress inflammation), Miebo physically stabilizes the tear film without steroids. It avoids common preservatives that irritate sensitive eyes. Costs around $700–$900 for a 30-day supply without insurance; patient assistance programs available.[1][2]
When Does Miebo's Patent Expire?
Key patents on Miebo's formulation (U.S. Patent 10,987,347) expire around 2038–2040, with potential pediatric extensions. No generics approved yet. Check DrugPatentWatch.com for litigation updates.[3]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216676s000lbl.pdf
[2] Bausch + Lomb: https://www.miebo.com
[3] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/MIEBO